Skip to main content
Top
Published in: Medical Oncology 1/2013

Open Access 01-03-2013 | Original Paper

Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival

Authors: Anna Niwińska, Halina Rudnicka, Magdalena Murawska

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

The aim of the study was to define biological subtypes of breast cancer that have the propensity to metastasize to the leptomeninges and to assess factors influencing survival from detection of leptomeningeal metastatis (LM). One hundred and eighteen consecutive breast cancer patients with LM were treated in one institution, between the years 1999 and 2009; 40.5 % of patients had triple-negative subtype, 37.5 % had luminal A subtype and 22 % had HER2-positive subtypes (luminal B and HER2). Of patients with LM, 35 % had lobular cancer. Median survival from the detection of LM was 18 weeks, and 1-year survival was 16 %. Cox multivariate analysis revealed that performance status and systemic treatment statistically significantly influenced survival of patients with LM. Triple-negative biological subtype and lobular histological type of breast cancer had the propensity to metastasize to the leptomeninges. Performance status and systemic treatment ordered after detection of LM statistically significantly influenced survival.
Literature
1.
go back to reference Fisher R, De Angelis LM. Leptomeningeal metastasis. In: Harris JR, Morrow M, Lippman ME, Osborne CK, editors. Disease of the Breast. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 1001–7. Fisher R, De Angelis LM. Leptomeningeal metastasis. In: Harris JR, Morrow M, Lippman ME, Osborne CK, editors. Disease of the Breast. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 1001–7.
3.
go back to reference Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis—the role of multimodality treatment. J Neurooncol. 2007;84:57–62.PubMedCrossRef Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis—the role of multimodality treatment. J Neurooncol. 2007;84:57–62.PubMedCrossRef
5.
go back to reference Niwińska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer. 2010;116:4238–47.PubMedCrossRef Niwińska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer. 2010;116:4238–47.PubMedCrossRef
6.
7.
go back to reference Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomathosis. Ann Oncol. 2010;21:2183–7.PubMedCrossRef Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomathosis. Ann Oncol. 2010;21:2183–7.PubMedCrossRef
8.
go back to reference Le Rhun E, Zairi F, Baranzelli MC. Primary breast cancer phenotype associated with propensity for leptomeningeal metastases. Eur J Cancer. 2010; 8:199 (Abstr. 479). Le Rhun E, Zairi F, Baranzelli MC. Primary breast cancer phenotype associated with propensity for leptomeningeal metastases. Eur J Cancer. 2010; 8:199 (Abstr. 479).
9.
go back to reference Altundag K, Bondy M, Mirza N, Kau SW, Brglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors of 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.PubMedCrossRef Altundag K, Bondy M, Mirza N, Kau SW, Brglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors of 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.PubMedCrossRef
10.
go back to reference Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809–17.PubMedCrossRef Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809–17.PubMedCrossRef
11.
go back to reference Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942–8.PubMedCrossRef Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942–8.PubMedCrossRef
12.
go back to reference Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–45.PubMedCrossRef Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–45.PubMedCrossRef
13.
go back to reference Reis-Filho JS, Tutt AN. Triple-negative tumors: a critical review. Histopathology. 2008;52:108–18.PubMedCrossRef Reis-Filho JS, Tutt AN. Triple-negative tumors: a critical review. Histopathology. 2008;52:108–18.PubMedCrossRef
14.
go back to reference Boogerd W, Hart AMH, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Cancer. 1991;67:1685–95.PubMedCrossRef Boogerd W, Hart AMH, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Cancer. 1991;67:1685–95.PubMedCrossRef
15.
go back to reference Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palange T, et al. Meningeal carcinomathosis in patients with breast carcinoma. Clinical features, prognostic factors and results of high-dose intrathecal methotrexate regimen. Cancer. 1996;77:1315–23.PubMedCrossRef Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palange T, et al. Meningeal carcinomathosis in patients with breast carcinoma. Clinical features, prognostic factors and results of high-dose intrathecal methotrexate regimen. Cancer. 1996;77:1315–23.PubMedCrossRef
16.
go back to reference de Azevedo CRA, Cruz MRS, Chinen LTD, Peres SV, Peterlevitz MA. de Azevedo Pereira AE et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104:565–72.PubMedCrossRef de Azevedo CRA, Cruz MRS, Chinen LTD, Peres SV, Peterlevitz MA. de Azevedo Pereira AE et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104:565–72.PubMedCrossRef
17.
go back to reference Wasserstrom WR, Glass P, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–72.PubMedCrossRef Wasserstrom WR, Glass P, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–72.PubMedCrossRef
18.
go back to reference Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol. 2009;66:74–8.PubMedCrossRef Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol. 2009;66:74–8.PubMedCrossRef
19.
go back to reference Lombardi G, Zustovich F, Farina P, Puppa AD, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16:1175–88.PubMedCrossRef Lombardi G, Zustovich F, Farina P, Puppa AD, Manara R, Cecchin D, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist. 2011;16:1175–88.PubMedCrossRef
20.
go back to reference Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in breast cancer: an aggressive disease variant. Cancer. 1994;74:3135–41.PubMedCrossRef Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in breast cancer: an aggressive disease variant. Cancer. 1994;74:3135–41.PubMedCrossRef
21.
go back to reference Yap H, Yap B, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982;49:219–22.CrossRef Yap H, Yap B, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982;49:219–22.CrossRef
22.
go back to reference Boogerd W, Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NC, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40:2726–33.PubMedCrossRef Boogerd W, Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NC, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40:2726–33.PubMedCrossRef
23.
go back to reference Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleucemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561–7.PubMed Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleucemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561–7.PubMed
24.
go back to reference Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994;51:457–61.PubMedCrossRef Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994;51:457–61.PubMedCrossRef
25.
go back to reference Bokstein F, Lossos A, Siegal T. Leptomeningeal metastasis from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.PubMedCrossRef Bokstein F, Lossos A, Siegal T. Leptomeningeal metastasis from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.PubMedCrossRef
26.
go back to reference Perez Segura P, Gil M, Balana C. Phase II trial of temozolomide for leptomeningeal metastases: safety and activity analysis. J Clin Oncol 2010;28 (supl):Abstract e 12528. Perez Segura P, Gil M, Balana C. Phase II trial of temozolomide for leptomeningeal metastases: safety and activity analysis. J Clin Oncol 2010;28 (supl):Abstract e 12528.
27.
go back to reference Kiewe P, Thiel E, Reinwald A, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neurooncol. 2011;103:629–34.PubMedCrossRef Kiewe P, Thiel E, Reinwald A, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neurooncol. 2011;103:629–34.PubMedCrossRef
28.
go back to reference Giglio P, Tremont-Lukas IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003;65:167–72.PubMedCrossRef Giglio P, Tremont-Lukas IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003;65:167–72.PubMedCrossRef
29.
go back to reference Rogers LR, Remer SE, Tejwani S. Durable response to breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neurooncol. 2004;6:63–4. Rogers LR, Remer SE, Tejwani S. Durable response to breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neurooncol. 2004;6:63–4.
30.
go back to reference Boogerd W, Dorrestejin LDA, van der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;55:117–9.PubMedCrossRef Boogerd W, Dorrestejin LDA, van der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;55:117–9.PubMedCrossRef
31.
go back to reference Baculi RH, Suki S, Nisbett J, Leeds N, Groves M. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol. 2001;19:3297–8.PubMed Baculi RH, Suki S, Nisbett J, Leeds N, Groves M. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol. 2001;19:3297–8.PubMed
32.
go back to reference Feyer P, Sautter-Bihl M-L, Budach W, Dunst J, Haase W, Harms W, et al. DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomathosis. Strahlenth Oncol. 2010;186:63–9.CrossRef Feyer P, Sautter-Bihl M-L, Budach W, Dunst J, Haase W, Harms W, et al. DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomathosis. Strahlenth Oncol. 2010;186:63–9.CrossRef
Metadata
Title
Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival
Authors
Anna Niwińska
Halina Rudnicka
Magdalena Murawska
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0408-4

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine